DGAP-Adhoc

Dr. Mariola Söhngen appointed as new CEO of MOLOGEN AG

MOLOGEN AG / Key word(s): Change of Personnel

23.07.2015 17:55

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc notification according to § 15 WpHG

Dr. Mariola Söhngen appointed as new CEO of MOLOGEN AG

Berlin, July 23, 2015. The Supervisory Board of MOLOGEN AG (ISIN
DE0006637200/WKN 663720) today appointed Dr. Mariola Söhngen, co-founder of
PAION AG (and Management Board member up to October 31, 2015, as Chief
Medical Officer; CMO), as Member of the Executive Board and new Chief
Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015.
She will be in charge of Research, Business Development, Strategy and
Partnering.

The presiding CEO of MOLOGEN AG, Dr. Matthias Schroff, has announced that
he will resign from his post as chairman of the Executive Board on October
31, 2015 and be leaving the Executive Board with effect from December 31,
2015, by mutual agreement with the Supervisory Board. In the interim period
from November 1, 2015 to December 31, 2015, Dr. Schroff will work as
Executive Board member in cooperation with Dr. Söhngen to ensure a smooth
transition of the chairmanship.

In addition, Jörg Petraß (Chief Financial Officer; CFO) has also informed
the Supervisory Board that he does not plan to extend his tenure as
Executive Board Member of MOLOGEN AG, which is due to run out on December
31, 2015. However, he has offered to act as a consultant for a
transitional period to enable orderly succession planning and the induction
of his successor.


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
[e-mail]


Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.

23.07.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: [e-mail]
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------